C4 Therapeutics (NASDAQ: CCCC), a leader in protein degradation, announced this week its strategic focus for 2024, which includes a significant reduction of 30% in its workforce. The U.S.-based company will prioritize ongoing Phase I/II trials for CFT7455 and CFT1946, targeting relapsed/refractory multiple myeloma (r/rMM) and BRAF V600X-mutant solid tumors, respectively. Additionally, C4 is advancing an internal drug discovery program alongside three collaborative efforts with Roche (SWX: ROG), Biogen (NASDAQ: BIIB), and Merck, Sharp & Dohme (MSD; NYSE: MRK).
The company is also continuing its development of candidate CFT8919, a metamorphic BiDA degradation agent licensed to Betta Pharmaceuticals (SHE: 300558) in December 2023. Betta recently received approval to initiate early trials in China for CFT8919 in patients with EGFR L858R-mutated non-small cell lung cancer (NSCLC).- Flcube.com
